The Asia Pacific Antiplatelet Market would witness market growth of 5.5% CAGR during the forecast period (2023-2030). In the year 2021, the Asia Pacific market's volume surged to 111.9 million Units, showcasing a growth of 4.0% (2019-2022).
The prevalence of antithrombotic/anticoagulant medications, the aging population, an upsurge in thrombotic events, and recent pharmaceutical advancements are some of the main factors driving the market. Antithrombotic agents are substances that prevent blood clotting from forming. Antithrombotic could be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a hazardous blood clot (acute thrombus).
The demand for antiplatelet pharmaceuticals is not limited to developed nations but is also witnessed in developing countries, which is anticipated to propel market growth. Additionally, the market for antiplatelets is expanding due to increased government initiatives for cardiovascular disorders, including stroke. Under the National Programme for the Prevention and Control of Cancer, Cardiovascular Diseases, Diabetes, and Stroke (NPCDCS), the Department of Health & Family Welfare, Government of India, provides technical and financial support to the States/UTs. Campaigns for awareness, screening programs, and subsidized access to drugs are frequently included in these activities.
As per International Trade Administration, in 2018, China's healthcare sector exhibited continuous, robust expansion and dynamic regulatory shifts. The sector for medical devices in China reached approximately USD 70 billion. The demand for medical devices has maintained double-digit growth for over a decade, making it one of China's fastest-growing markets. Over 70% of this expansion had attributable to hospital procurement. In recent years, the Asia Pacific region has seen a considerable rise in research and development (R&D) activities related to antiplatelet therapies and cardiovascular medicine. Hence, with the expanding disease burden and healthcare sector, the market will grow throughout the forecast period.
The China market dominated the Asia Pacific Antiplatelet Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $347.9 Million by 2030. The Japan market is registering a CAGR of 4.8% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 6.1% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drug Class, the market is segmented into Adenosine diphosphate (ADP) Receptor Inhibitors, Irreversible Inhibitors Cyclooxygenase, and Others. Based on Distribution Channel, the market is segmented into Drug store & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Global Antiplatelet Market is Predict to reach $5.1 Billion by 2030, at a CAGR of 4.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cipla Limited, Glenmark Pharmaceuticals Limited, Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A. , Lupin Limited and Chiesi Farmaceutici S.p.A.
By Route of Administration (Volume, Million Units, USD Million, 2019-2030)
By Drug Class (Volume, Million Units, USD Million, 2019-2030)
By Distribution Channel (Volume, Million Units, USD Million, 2019-2030)
By Country (Volume, Million Units, USD Million, 2019-2030)
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
